Hsien-Yen Chang1, Tatyana Lyapustina2, Lainie Rutkow3, Matthew Daubresse4, Matt Richey5, Mark Faul6, Elizabeth A Stuart7, G Caleb Alexander8. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway St., Baltimore, MD 21205, United States; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States. Electronic address: hchang24@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States. Electronic address: tlyapus1@jhmi.edu. 3. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway St., Baltimore, MD 21205, United States. Electronic address: lrutkow@jhu.edu. 4. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States. Electronic address: mdaubre1@jhu.edu. 5. Department of Mathematics, Statistics, and Computer Science, St. Olaf College, Regents Hall of Science 302, Northfield, MN 55057, United States. Electronic address: richeym@stolaf.edu. 6. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 4770 Buford Hwy, NE Mail Stop MS F-63 Atlanta, GA 30341, United States. Electronic address: mgf7@cdc.gov. 7. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway St., Baltimore, MD 21205, United States; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, 8th Floor, Baltimore, MD 21205, United States; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, 8th Floor, Baltimore, MD 21205, United States. Electronic address: estuart@jhsph.edu. 8. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. W6035, Baltimore, MD 21205, United States; Division of General Internal Medicine, Johns Hopkins Medicine, 615 N Wolfe St., Baltimore, MD 21205, United States. Electronic address: galexand@jhsph.edu.
Abstract
BACKGROUND: Prescription drug monitoring programs (PDMPs) and pill mill laws were implemented to reduce opioid-related injuries/deaths. We evaluated their effects on high-risk prescribers in Florida. METHODS: We used IMS Health's LRx Lifelink database between July 2010 and September 2012 to identify opioid-prescribing prescribers in Florida (intervention state, N: 38,465) and Georgia (control state, N: 18,566). The pre-intervention, intervention, and post-intervention periods were: July 2010-June 2011, July 2011-September 2011, and October 2011-September 2012. High-risk prescribers were those in the top 5th percentile of opioid volume during four consecutive calendar quarters. We applied comparative interrupted time series models to evaluate policy effects on clinical practices and monthly prescribing measures for low-risk/high-risk prescribers. RESULTS: We identified 1526 (4.0%) high-risk prescribers in Florida, accounting for 67% of total opioid volume and 40% of total opioid prescriptions. Relative to their lower-risk counterparts, they wrote sixteen times more monthly opioid prescriptions (79 vs. 5, p<0.01), and had more prescription-filling patients receiving opioids (47% vs. 19%, p<0.01). Following policy implementation, Florida's high-risk providers experienced large relative reductions in opioid patients and opioid prescriptions (-536 patients/month, 95% confidence intervals [CI] -829 to -243; -847 prescriptions/month, CI -1498 to -197), morphine equivalent dose (-0.88mg/month, CI -1.13 to -0.62), and total opioid volume (-3.88kg/month, CI -5.14 to -2.62). Low-risk providers did not experience statistically significantly relative reductions, nor did policy implementation affect the status of being high- vs. low- risk prescribers. CONCLUSIONS: High-risk prescribers are disproportionately responsive to state policies. However, opioids-prescribing remains highly concentrated among high-risk providers.
BACKGROUND: Prescription drug monitoring programs (PDMPs) and pill mill laws were implemented to reduce opioid-related injuries/deaths. We evaluated their effects on high-risk prescribers in Florida. METHODS: We used IMS Health's LRx Lifelink database between July 2010 and September 2012 to identify opioid-prescribing prescribers in Florida (intervention state, N: 38,465) and Georgia (control state, N: 18,566). The pre-intervention, intervention, and post-intervention periods were: July 2010-June 2011, July 2011-September 2011, and October 2011-September 2012. High-risk prescribers were those in the top 5th percentile of opioid volume during four consecutive calendar quarters. We applied comparative interrupted time series models to evaluate policy effects on clinical practices and monthly prescribing measures for low-risk/high-risk prescribers. RESULTS: We identified 1526 (4.0%) high-risk prescribers in Florida, accounting for 67% of total opioid volume and 40% of total opioid prescriptions. Relative to their lower-risk counterparts, they wrote sixteen times more monthly opioid prescriptions (79 vs. 5, p<0.01), and had more prescription-filling patients receiving opioids (47% vs. 19%, p<0.01). Following policy implementation, Florida's high-risk providers experienced large relative reductions in opioid patients and opioid prescriptions (-536 patients/month, 95% confidence intervals [CI] -829 to -243; -847 prescriptions/month, CI -1498 to -197), morphine equivalent dose (-0.88mg/month, CI -1.13 to -0.62), and total opioid volume (-3.88kg/month, CI -5.14 to -2.62). Low-risk providers did not experience statistically significantly relative reductions, nor did policy implementation affect the status of being high- vs. low- risk prescribers. CONCLUSIONS: High-risk prescribers are disproportionately responsive to state policies. However, opioids-prescribing remains highly concentrated among high-risk providers.
Authors: Matthew Daubresse; Hsien-Yen Chang; Yuping Yu; Shilpa Viswanathan; Nilay D Shah; Randall S Stafford; Stefan P Kruszewski; G Caleb Alexander Journal: Med Care Date: 2013-10 Impact factor: 2.983
Authors: Teryl K Nuckols; Laura Anderson; Ioana Popescu; Allison L Diamant; Brian Doyle; Paul Di Capua; Roger Chou Journal: Ann Intern Med Date: 2014-01-07 Impact factor: 25.391
Authors: Roger Chou; Judith A Turner; Emily B Devine; Ryan N Hansen; Sean D Sullivan; Ian Blazina; Tracy Dana; Christina Bougatsos; Richard A Deyo Journal: Ann Intern Med Date: 2015-02-17 Impact factor: 25.391
Authors: Leonard J Paulozzi; Edwin M Kilbourne; Nina G Shah; Kurt B Nolte; Hema A Desai; Michael G Landen; William Harvey; Larry D Loring Journal: Pain Med Date: 2011-10-25 Impact factor: 3.750
Authors: Jane A Gwira Baumblatt; Caleb Wiedeman; John R Dunn; William Schaffner; Leonard J Paulozzi; Timothy F Jones Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Tatyana Lyapustina; Lainie Rutkow; Hsien-Yen Chang; Matthew Daubresse; Alim F Ramji; Mark Faul; Elizabeth A Stuart; G Caleb Alexander Journal: Drug Alcohol Depend Date: 2015-12-31 Impact factor: 4.492
Authors: Elizabeth M Stone; Lainie Rutkow; Mark C Bicket; Colleen L Barry; G Caleb Alexander; Emma E McGinty Journal: Drug Alcohol Depend Date: 2020-06-11 Impact factor: 4.492
Authors: Victor Puac-Polanco; Stanford Chihuri; David S Fink; Magdalena Cerdá; Katherine M Keyes; Guohua Li Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 6.222
Authors: Hsien-Yen Chang; Noa Krawczyk; Kristin E Schneider; Lindsey Ferris; Matthew Eisenberg; Tom M Richards; B Casey Lyons; Kate Jackson; Jonathan P Weiner; Brendan Saloner Journal: Drug Alcohol Depend Date: 2019-06-07 Impact factor: 4.492
Authors: Brendan Saloner; Emma E McGinty; Leo Beletsky; Ricky Bluthenthal; Chris Beyrer; Michael Botticelli; Susan G Sherman Journal: Public Health Rep Date: 2018 Nov/Dec Impact factor: 2.792